76 related articles for article (PubMed ID: 11911404)
1. Efficacy of splenectomy for patients with mantle cell non-Hodgkin's lymphoma.
Yoong Y; Kurtin PJ; Allmer C; Geyer S; Habermann TM; Nagorney DM; Witzig TE
Leuk Lymphoma; 2001; 42(6):1235-41. PubMed ID: 11911404
[TBL] [Abstract][Full Text] [Related]
2. Splenectomy in advanced chronic lymphocytic leukemia: a single institution experience with 50 patients.
Neal TF; Tefferi A; Witzig TE; Su J; Phyliky RL; Nagorney DM
Am J Med; 1992 Oct; 93(4):435-40. PubMed ID: 1415307
[TBL] [Abstract][Full Text] [Related]
3. Splenectomy in mantle cell lymphoma with leukaemia: a comparison with chronic lymphocytic leukaemia.
Ruchlemer R; Wotherspoon AC; Thompson JN; Swansbury JG; Matutes E; Catovsky D
Br J Haematol; 2002 Sep; 118(4):952-8. PubMed ID: 12199772
[TBL] [Abstract][Full Text] [Related]
4. Value of splenectomy in non-Hodgkin's lymphoma.
Kehoe JE; Daly JM; Straus DJ; DeCosse JJ
Cancer; 1985 Mar; 55(6):1256-64. PubMed ID: 2578865
[TBL] [Abstract][Full Text] [Related]
5. Splenectomy for non-Hodgkin's lymphoma.
Brodsky J; Abcar A; Styler M
Am J Clin Oncol; 1996 Dec; 19(6):558-61. PubMed ID: 8931670
[TBL] [Abstract][Full Text] [Related]
6. Splenectomy for hypersplenism in chronic lymphocytic leukaemia and malignant non-Hodgkin's lymphoma.
Delpero JR; Houvenaeghel G; Gastaut JA; Orsoni P; Blache JL; Guerinel G; Carcassonne Y
Br J Surg; 1990 Apr; 77(4):443-9. PubMed ID: 2340397
[TBL] [Abstract][Full Text] [Related]
7. Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma.
O'Connor OA; Wright J; Moskowitz C; Muzzy J; MacGregor-Cortelli B; Stubblefield M; Straus D; Portlock C; Hamlin P; Choi E; Dumetrescu O; Esseltine D; Trehu E; Adams J; Schenkein D; Zelenetz AD
J Clin Oncol; 2005 Feb; 23(4):676-84. PubMed ID: 15613699
[TBL] [Abstract][Full Text] [Related]
8. Splenectomy for massive splenomegaly: long-term results and risks for mortality.
Taner T; Nagorney DM; Tefferi A; Habermann TM; Harmsen WS; Slettedahl SW; Donohue JH
Ann Surg; 2013 Dec; 258(6):1034-9. PubMed ID: 23222031
[TBL] [Abstract][Full Text] [Related]
9. The leukemic presentation of mantle-cell lymphoma: disease features and prognostic factors in 58 patients.
Matutes E; Parry-Jones N; Brito-Babapulle V; Wotherspoon A; Morilla R; Atkinson S; Elnenaei MO; Jain P; Giustolisi GM; A'Hern RP; Catovsky D
Leuk Lymphoma; 2004 Oct; 45(10):2007-15. PubMed ID: 15370245
[TBL] [Abstract][Full Text] [Related]
10. Still a role for surgery as first-line therapy of splenic marginal zone lymphoma? Results of a prospective observational study.
Pata G; Bartoli M; Damiani E; Solari S; Anastasia A; Pagani C; Tucci A
Int J Surg; 2017 May; 41():143-149. PubMed ID: 28366762
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide/fludarabine (CF) is active in the treatment of mantle cell lymphoma.
Cohen BJ; Moskowitz C; Straus D; Noy A; Hedrick E; Zelenetz A
Leuk Lymphoma; 2001; 42(5):1015-22. PubMed ID: 11697618
[TBL] [Abstract][Full Text] [Related]
12. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine.
Romaguera JE; Fayad L; Rodriguez MA; Broglio KR; Hagemeister FB; Pro B; McLaughlin P; Younes A; Samaniego F; Goy A; Sarris AH; Dang NH; Wang M; Beasley V; Medeiros LJ; Katz RL; Gagneja H; Samuels BI; Smith TL; Cabanillas FF
J Clin Oncol; 2005 Oct; 23(28):7013-23. PubMed ID: 16145068
[TBL] [Abstract][Full Text] [Related]
13. Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma.
Robinson KS; Williams ME; van der Jagt RH; Cohen P; Herst JA; Tulpule A; Schwartzberg LS; Lemieux B; Cheson BD
J Clin Oncol; 2008 Sep; 26(27):4473-9. PubMed ID: 18626004
[TBL] [Abstract][Full Text] [Related]
14. The value of splenectomy in chronic lymphocytic leukemia.
Delpero JR; Gastaut JA; Letreut YP; Caamano A; Mathieu-Tubiana N; Maraninchi D; Simon-Lejeune C; Mascret B; Blanc AP; Sebahoun G
Cancer; 1987 Jan; 59(2):340-5. PubMed ID: 3802020
[TBL] [Abstract][Full Text] [Related]
15. Intensive chemotherapy with hematopoietic cell transplantation after ESHAP therapy for relapsed or refractory non-Hodgkin's lymphoma. Results of a single-centre study of 65 patients.
Soussain C; Souleau B; Gabarre J; Zouabi H; Sutton L; Boccaccio C; Albin N; Charlotte F; Merle-Béral H; Delort J; Binet JL; Leblond V
Leuk Lymphoma; 1999 May; 33(5-6):543-50. PubMed ID: 10342581
[TBL] [Abstract][Full Text] [Related]
16. A 10-year experience with splenectomy in patients with malignant non-Hodgkin's lymphoma at the Norwegian Radium Hospital.
Lehne G; Hannisdal E; Langholm R; Nome O
Cancer; 1994 Aug; 74(3):933-9. PubMed ID: 8039121
[TBL] [Abstract][Full Text] [Related]
17. Role of splenectomy in chronic lymphocytic leukaemia with massive splenomegaly and cytopenia.
Majumdar G; Singh AK
Leuk Lymphoma; 1992 May; 7(1-2):131-4. PubMed ID: 1472923
[TBL] [Abstract][Full Text] [Related]
18. Longer-term follow-up and outcome by tumour cell proliferation rate (Ki-67) in patients with relapsed/refractory mantle cell lymphoma treated with lenalidomide on MCL-001(EMERGE) pivotal trial.
Goy A; Kalayoglu Besisik S; Drach J; Ramchandren R; Robertson MJ; Avivi I; Rowe JM; Herbrecht R; Van Hoof A; Zhang L; Cicero S; Fu T; Witzig T
Br J Haematol; 2015 Aug; 170(4):496-503. PubMed ID: 25921098
[TBL] [Abstract][Full Text] [Related]
19. [Splenectomy in immune thrombocytopenia and other hematological diseases].
Lanzi S; Lancini GP; Piardi T; Biasca F; Ottaviani GM; Rossi G; Pizzoccaro C; Pouchè A
G Chir; 1999; 20(11-12):479-86. PubMed ID: 10645065
[TBL] [Abstract][Full Text] [Related]
20. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
Rasmussen PK
Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
